Relay Therapeutics, Inc. SEC filings RLAY
Relay Therapeutics, Inc. has 556 filings in SEC EDGAR's recent list, going back to May 22, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Jan 10, 2024 | — |
| EFFECT | Filing | May 6, 2021 | — |
| CORRESP | Letter to the SEC | May 4, 2021 | — |
| UPLOAD | Letter from the SEC | May 3, 2021 | — |
| EFFECT | Filing | Jul 15, 2020 | — |
| CERT | Filing | Jul 15, 2020 | — |
| CORRESP | Letter to the SEC | Jul 14, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2020 | — |
| 8-A12B | Filing | Jul 13, 2020 | — |
| CORRESP | Letter to the SEC | Jul 13, 2020 | — |
| CORRESP | Letter to the SEC | Jul 13, 2020 | — |
| CORRESP | Letter to the SEC | Jul 9, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2020 | — |
| CORRESP | Letter to the SEC | Jun 25, 2020 | — |
| CORRESP | Letter to the SEC | Jun 24, 2020 | — |
| DRS/A | Filing | Jun 22, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 19, 2020 | — |
| DRS | Filing | May 22, 2020 | — |
Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RLAY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1812364
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.